SEC Form 4 · accession 0001415889-16-006881
Niagen Bioscience, Inc. · NAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank L Jaksch Jr.
Officer — CEO, PRESIDENT · Director
Period of report
Aug 15, 2016
Accepted (ET)
Aug 17, 2016 · 4:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001386570
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Options (right to buy)F1 | $4.04 | Aug 15, 2016 | A | 85,000 | A | Jul 14, 2017 | Aug 15, 2026 | Common Stock | 85,000 | 85,000 | D |
Explanation of responses
- F1Options vest 25% on July 14, 2017 with the remainder vesting 1/36th per month over three years thereafter.